University of California San Francisco
San Francisco, California, 94110, United States
Location status: Recruiting
NCT Number: NCT04359186
The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
San Francisco, California, 94110, United States
Location status: Recruiting
In this study, people living with HIV will undergo intensive sampling prior to and following an interruption of their antiretroviral therapy (ART). Individuals will be asked to resume ART once the virus is detectable, or after approximately three weeks if the virus remains undetectable.
Individuals who were able to control their virus before ART ("controllers") will be able to participate in an extended treatment interruption and have less restrictive ART restart criteria.
The overall goal of the study is to characterize the interaction between the host and the virus at the earliest stages of virus replication and to identify predictors of rebound before virus becomes detectable.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Individuals with HIV on suppressive ART will interrupt their ART.
Time frame: Week 0 through Month 6
The proportion of participants developing acute retroviral syndrome
Time frame: Week 0 through Month 12
The proportion of participants who fail to re-suppress to plasma HIV RNA levels <50 copies/mL after re-initiating ART
Time frame: Week 0 through Month 6
The proportion of participants with confirmed decreases in CD4+ T cell count below 350 cells/uL
Time frame: Week 0 through Month 6
The time between the treatment interruption and plasma HIV RNA >200 copies/mL
Contact information is provided by the study sponsor or research team.
University of California, San Francisco
Other
Analytic Treatment Interruption in HIV Infection
Acronym: SCOPE-ATI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07072481
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Yaba, Lagos, Nigeria
View Trial DetailsNCT06949774
Acquired Immunodeficiency Syndrome, Behavior
Kampala, Uganda
View Trial DetailsNCT06741618
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
New York, United States
View Trial DetailsNCT05330923
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Beijing, Beijing Municipality, China
View Trial Details